One of the most exciting developments in the fight against cancer in the last few years has been the advancement of targeted therapy drugs. The Seattle-based firm Seattle Genetics founded and led by Dr. Clay Siegall has become an industry leader in this exciting and comparatively new field. The mortality rate has not substantially improved for certain diseases in decades, and Dr. Siegall and his associates at Seattle Genetics are working toward changing that.
What started as a small startup with only a few researchers in 1998 has grown into one of the industry leaders in cancer research. Seattle Genetic has developed the first FDA-approved drug of this type and now has multiple approved applications leading to over 20 partnerships with pharmaceutical companies such as Pfizer, Genentech, and several others. Dr. Siegall is very excited about the future of the company, citing the growing list of new drugs in development stages and the increasing number of potential applications for his existing portfolio. Believing traditional forms of cancer treatment are destined for obscurity and will be replaced with targeted drug therapies as they are more tolerable and much more efficient. Dr. Siegall is confident Seattle Genetics will be a leader in the drug development industry for the 21st century.
Clay Siegall has always been interested in medicine, and the influence technology can have in the treatment of disease. He became interested in cancer treatment while studying zoology at the University of Maryland where he earned a B.S., he also holds a Ph.D. in genetics from George Washington University. While attending the University of Maryland, a member of his family was afflicted with cancer. He soon discovered the treatment was almost worse than cancer itself, the chemotherapy almost caused his family member to die. Other forms of treatment such as radical surgery and amputation convinced him there had to be a better way.
Before founding Seattle Genetics where he is the current CEO Dr. Siegall worked at the Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Siegall left Bristol-Myers for several reasons, he did not like the restraints and felt he was not adequately compensated for the work he was doing. Citing one of his patients, he holds nine, that made Bristol-Myers $80 million and all he saw was a paycheck. Dr. Siegall has authored over 65 scientific articles and serves on the board of three scientific journals.